Shire plc today announced the results of a Phase II study indicating that FOSRENOL can effectively reduce serum phosphate levels in chronic kidney disease patients not on dialysis. FOSRENOL is a non-calcium phosphate binder, indicated to treat hyperphosphatemia in end stage renal disease , also known as CKD Stage 5.
Read More...
[Source: Yahoo! News Search Results for liver disease help]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment